Welcome to our dedicated page for Nanobiotix S.A. news (Ticker: NBTX), a resource for investors and traders seeking the latest updates and insights on Nanobiotix S.A. stock.
Nanobiotix S.A. (NBTX) is a clinical-stage biotechnology leader developing nanoparticle-enhanced radiotherapy solutions through its proprietary NanoXray platform. This dedicated news hub provides investors and healthcare professionals with essential updates on clinical trials, regulatory developments, and strategic partnerships.
Access timely reports on NBTXR3's progress across multiple cancer types including head and neck tumors and soft tissue sarcoma. Our curated collection features earnings announcements, research milestones, and technology licensing updates that demonstrate Nanobiotix's commitment to advancing precision radiotherapy.
Key content includes trial phase results, manufacturing partnerships, and scientific presentations detailing nanoparticle-enhanced treatment mechanisms. Bookmark this page for structured access to verified information about Nanobiotix's innovative approach to improving radiotherapy outcomes while protecting healthy tissue.
Nanobiotix will release its financial results for Q3 2022 on November 9, 2022, after US market close. A conference call is scheduled for November 10, 2022, at 8:00 AM ET, where CEO Laurent Levy and CFO Bart Van Rhijn will discuss the results and company updates. The call will be accessible via the company's website, allowing participants to register in advance. Nanobiotix focuses on innovative cancer therapies, particularly through its lead product, radiotherapy-activated NBTXR3, targeting solid tumors.
Nanobiotix (NASDAQ: NBTX) has signed a final restructuring agreement with the European Investment Bank (EIB) to realign approximately €30.7 million in debt obligations with its commercialization timelines. The agreement allows deferral of €25.3 million in principal repayments until June 2029 and restructures €5.4 million in accrued interest as payment-in-kind until October 2024. Additionally, a new €20 million milestone payment is set for June 2029, contingent on commercial success. This restructuring aims to support the anticipated revenue generation from the company’s lead product, NBTXR3, in cancer treatment.
Nanobiotix reported updated information regarding its outstanding shares and voting rights as of September 30, 2022. Currently, there are 34,875,872 shares outstanding, with a total of 36,277,898 theoretical voting rights and 36,261,825 exercisable voting rights. This data is crucial for ensuring transparency for shareholders and aligns with the French regulatory requirements.
Nanobiotix announced operational progress in its pivotal Phase 3 study, NANORAY-312, focusing on elderly patients with locally advanced head and neck cancer. The first patient has been enrolled in Asia, with plans to recruit approximately 100 patients globally. Financially, the company reported €63 million in cash equivalents as of June 30, 2022, and expects funding through Q1 2024 due to a debt restructuring with the EIB. Despite a stable revenue of €1.3 million, R&D expenses rose to €16.6 million. The net loss decreased to €26.4 million, or €0.76 per share, compared to €30.4 million in 2021.
Nanobiotix plans to report its financial results for the half-year ending
Nanobiotix (NASDAQ: NBTX) announced the recommended phase 2 dose for NBTXR3, which is set at 33% of gross tumor volume in three cohorts for treating head and neck squamous cell carcinoma (HNSCC). The company expects to submit a Phase 3 trial protocol to the FDA by Q1 2023, with updated clinical data from Study 1100 anticipated in Q4 2022. The ongoing study aims to evaluate NBTXR3 in combination with anti-PD-1 therapies for patients with recurrent or metastatic HNSCC, including those resistant to previous immunotherapy.
Nanobiotix reached an agreement to restructure €30.7 million in debt obligations from its 2018 loan with the European Investment Bank (EIB). This restructuring aims to align debt with development timelines, extending the maturity dates to June 2029 for principal repayments and October 2024 for interest payments. This extension will enhance Nanobiotix's operational runway into early 2024, allowing focus on lead programs for its cancer treatment, NBTXR3. Execution of the amendment is expected in Q4 2022, contingent on final legal documentation.
On August 31, 2022, Nanobiotix reported a total of 34,875,872 shares outstanding, with voting rights totaling 36,274,272 theoretical rights and 36,250,130 exercisable rights. This announcement aligns with regulations from the French Financial Markets Authority, ensuring transparency in shareholder voting. Nanobiotix focuses on innovative therapeutic approaches for cancer treatment, utilizing its nanoparticle technology, specifically targeting head and neck cancers. Investors can find further details on their official website.
Nanobiotix and LianBio have announced the enrollment of the first patient in the pivotal Phase 3 NANORAY-312 trial for NBTXR3, targeting elderly patients with locally advanced head and neck cancer ineligible for platinum-based chemotherapy. This trial will assess the effectiveness of NBTXR3 combined with radiotherapy and cetuximab. With a global enrollment goal of 500 patients, LianBio aims to enroll approximately 100 in Asia. Previous trials show promising survival rates, positioning NBTXR3 as a potential key treatment in a rapidly growing radiotherapy market in Asia.
FAQ
What is the current stock price of Nanobiotix S.A. (NBTX)?
What is the market cap of Nanobiotix S.A. (NBTX)?
